CTN Webinar: Relapse Prevention.
CTN Webinar: Relapse Prevention. – This 90-minute webinar, produced by the National Drug Abuse Treatment Clinical Trials Network (CTN) Clinical Coordinating Center for CTN members and the public, explores the issue of relapse among individuals with substance use disorders (SUD). Outcome studies, types and effects of lapse and relapse, and factors contributing to relapse are reviewed. A major emphasis of the webinar is on discussing specific clinical strategies to reduce relapse risk, with a focus on current empirical and clinical literature, including findings from quality improvement studies and clinical trials conducted in a drug treatment clinic. The target audience is CTN members and other researchers and clinicians interested in learning more about relapse prevention. Presented by Dennis Daley, PhD, LSW (Western Psychiatric Institute and Clinic, AT Node) and Dennis M. Donovan, PhD (Alcohol & Drug Abuse Institute, University of Washington, PN Node). For more resources related to this webinar, as well as other webinars in this series, visit: ctndisseminationlibrary.org
Surgical Theater, LLC™ Receives FDA Clearance for Surgery Rehearsal …
Filed under: drug abuse treatment outcome study
27, 2013 — /PRNewswire/ — Surgical Theater, LLC™, has received Food and Drug Administration clearance of their Selman Surgery Rehearsal Platform™(SRP), making it the only patented and FDA cleared platform for cerebral and spine pre-surgery …
Read more on Sacramento Bee
Shionogi Receives FDA Approval For Osphena™ (Ospemifene) For The …
Filed under: drug abuse treatment outcome study
26, 2013 — /PRNewswire/ — Shionogi Inc., the United States (U.S.)-based company of Shionogi & Co., Ltd., today announced that the U.S. Food and Drug Administration (FDA) has approved Osphena™ (ospemifene) tablets for the treatment of moderate to …
Read more on Sacramento Bee
Durect Offers Two Shots On Goal, Almost 100% Upside
Filed under: drug abuse treatment outcome study
This is a pesky assay to perform on a drug like Remoxy given that the drug was designed by Durect with its ORADUR technology specifically to not dissolve and release oxycodone at a rate that would create abuse or misuse potential. Nevertheless, an …
Read more on Seeking Alpha